Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Patients presenting to the emergency department with an acute ischemic stroke due to a large
vessel occlusion eligible for thrombectomy and target mismatch on computed tomography
perfusion imaging within 24 hours of onset will be assessed determine their eligibility for
randomization into the trial. If the patient gives informed consent they will be randomised
using a central computerised allocation process to either standard of care (no intravenous
thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing
intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded
endpoint (PROBE) design.